JP2020515579A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515579A5
JP2020515579A5 JP2019553168A JP2019553168A JP2020515579A5 JP 2020515579 A5 JP2020515579 A5 JP 2020515579A5 JP 2019553168 A JP2019553168 A JP 2019553168A JP 2019553168 A JP2019553168 A JP 2019553168A JP 2020515579 A5 JP2020515579 A5 JP 2020515579A5
Authority
JP
Japan
Prior art keywords
viable
biopharmacy
ingestible device
biologic
ingestible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515579A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025540 external-priority patent/WO2018183941A2/en
Publication of JP2020515579A publication Critical patent/JP2020515579A/ja
Publication of JP2020515579A5 publication Critical patent/JP2020515579A5/ja
Pending legal-status Critical Current

Links

JP2019553168A 2017-03-30 2018-03-30 消化管疾病の生菌生物学的製剤による治療 Pending JP2020515579A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762479027P 2017-03-30 2017-03-30
US62/479,027 2017-03-30
US201762545297P 2017-08-14 2017-08-14
US62/545,297 2017-08-14
US201762583932P 2017-11-09 2017-11-09
US62/583,932 2017-11-09
US201762596040P 2017-12-07 2017-12-07
US62/596,040 2017-12-07
US201762598948P 2017-12-14 2017-12-14
US62/598,948 2017-12-14
PCT/US2018/025540 WO2018183941A2 (en) 2017-03-30 2018-03-30 Treatment of a disease of the gastrointestinal tract with live biotherapeutics

Publications (2)

Publication Number Publication Date
JP2020515579A JP2020515579A (ja) 2020-05-28
JP2020515579A5 true JP2020515579A5 (https=) 2021-05-06

Family

ID=62116539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553168A Pending JP2020515579A (ja) 2017-03-30 2018-03-30 消化管疾病の生菌生物学的製剤による治療

Country Status (6)

Country Link
US (1) US20210401895A1 (https=)
EP (1) EP3601531B1 (https=)
JP (1) JP2020515579A (https=)
AU (1) AU2018244922A1 (https=)
CA (1) CA3054947A1 (https=)
WO (1) WO2018183941A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213579A1 (en) 2017-05-17 2018-11-22 Massachusetts Institute Of Technology Self-actuating articles
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
AU2019269636A1 (en) 2018-05-17 2020-11-19 Massachusetts Institute Of Technology Systems for electrical stimulation
KR102424237B1 (ko) * 2018-10-30 2022-07-21 비타볼러스 인크. 치료용 포유동물 세포의 경구 전달
EP4696361A3 (en) 2019-02-01 2026-04-15 Massachusetts Institute of Technology Systems and methods for liquid injection
WO2020185326A1 (en) * 2019-03-12 2020-09-17 Tidhar Shalon Devices and methods for collecting gastrointestinal samples
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
JP6667859B1 (ja) * 2019-05-31 2020-03-18 株式会社Kortuc 放射線又は抗がん化学療法増感剤投与ホルダー
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
CN111528219B (zh) * 2020-05-13 2022-03-15 上海市计量测试技术研究院 一种用于t淋巴细胞亚群计数标准物质的冻干保护剂及其应用
EP4247268A4 (en) 2020-11-23 2024-10-02 Envivo Bio Inc DEVICES AND METHODS FOR SAMPLING GASTROINTESTINAL FLUIDS AND ASSESSING GASTROINTESTINAL FUNCTION
WO2022159555A1 (en) * 2021-01-20 2022-07-28 The Trustees Of Columbia University In The City Of New York Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof
CN114288557B (zh) * 2021-12-30 2022-07-15 常师萌 一种多模式可自适应的肛肠冷热磁疗仪及调节系统
WO2026020057A1 (en) * 2024-07-17 2026-01-22 Prometheus Laboratories Inc. Serology repertoire for the diagnosis and prognosis of inflammatory bowel disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
AU636110B2 (en) 1988-06-08 1993-04-22 Nichols Institute Diagnostics Assays utilizing sensitizer-induced production of detectable signal
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
EP0463101B2 (en) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
ATE161850T1 (de) 1989-07-19 1998-01-15 Connetics Corp T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2679899A (en) 1998-02-18 1999-09-06 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
US6949347B2 (en) 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
AU2004275804A1 (en) 2003-09-23 2005-04-07 Light Sciences Oncology, Inc. Conjugates for photodynamic therapy
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ATE541469T1 (de) 2005-12-29 2012-02-15 Hills Pet Nutrition Inc Verfahren zum modifizieren der darmflora bei tieren
EP2040724B1 (en) 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
NZ612888A (en) 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
WO2010063743A1 (en) 2008-12-03 2010-06-10 Cellerix, S.A. Methods for the preparation of adipose derived stem cells and utilizing said cells in the treatment of diseases
ES2778836T3 (es) 2009-03-05 2020-08-12 Probiotical Spa Cepas de bacterias que tienen una alta actividad antiinflamatoria
GB2489193A (en) 2010-10-29 2012-09-26 Univ Warwick Ingestible sensor device to detect gases and VOCs in the gastrointestinal tract
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
SG11201509371XA (en) 2013-05-24 2015-12-30 Nestec Sa Pathway specific markers for diagnosing irritable bowel syndrome
US9772325B2 (en) 2013-06-14 2017-09-26 Biotranex, Llc Method for measuring bile salt export transport and/or formation activity
EP3052943B1 (en) * 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
WO2015070077A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
WO2015112575A1 (en) 2014-01-22 2015-07-30 The Board Of Regents Of The University Of Nebraska Gastrointestinal sensor implantation system
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
WO2016033638A1 (en) 2014-09-02 2016-03-10 Royal Melbourne Institute Of Technology Gas sensor nanocomposite membranes
EP4706525A3 (en) * 2014-09-25 2026-04-22 BT Bidco, Inc. Electromechanical pill device with localization capabilities
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
BR112017018656B1 (pt) 2015-03-02 2021-11-30 Synlogic, Inc Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida
WO2016172380A1 (en) 2015-04-21 2016-10-27 Epibiome, Inc. Compositions and methods for increasing the susceptibility of bacteria to antibiotics
JP2018517142A (ja) 2015-06-12 2018-06-28 ロイヤル・メルボルン・インスティテュート・オブ・テクノロジーRoyal Melbourne Institute Of Technology NOxガスセンサー
EP3322797B1 (en) 2015-07-13 2023-11-29 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease

Similar Documents

Publication Publication Date Title
JP2020515579A5 (https=)
JP2020502126A5 (https=)
JP2020501699A5 (https=)
JP2020513414A5 (https=)
ES2987408T3 (es) Una formulación de fármaco de liberación retardada
Ibekwe et al. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery
ES2390106T5 (es) Formulación para aporte colónico de fármacos
Stollman et al. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients
JP2021098727A5 (https=)
US11141440B2 (en) Pharmaceutical oral formulation comprising bacteria
CN105555260B (zh) 延迟释放的药物制剂
US9861585B2 (en) Osmotic floating tablets
ES2569354T3 (es) Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica
EP3319619A1 (en) Methods of treating colitis
JP2014221827A5 (https=)
Ying et al. Theranostic gastrointestinal residence systems
TW200502008A (en) Patches for mucosa of oral cavity containing fentanyl
CN101287443A (zh) pH控制的脉冲释放系统、其制备方法和用途
JP2018500546A5 (https=)
Yaghoubi et al. Therapeutic effect of an anti-tuberculosis agent, isoniazid, and its nano-isoform in ulcerative colitis
US11903923B2 (en) Use of andrographolide derivatives in preparation of medicaments for preventing and treating inflammatory bowel diseases
ZA202103678B (en) Colonic drug delivery formulation
MY194945A (en) Oral administration of unstable or poorly-absorbed drugs
翁孟慈 et al. Colonic Bleeding Caused by an Ingested Fishbone: Report of a Case
WO2022066110A1 (en) Pharmaceutical compositions comprising mesalamin and relevant excipients